Chemotherapy-Free Strategy for Platinum-Sensitive Recurrent Ovarian Cancer

The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(19)30714-4
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Elsevier BV

Related search

Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study

Asian Pacific Journal of Cancer Prevention
2019English

Secondary Cytoreduction Surgery Improves Prognosis in Platinum-Sensitive Recurrent Ovarian Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2013English

Extending the Platinum‐Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second‐Line Chemotherapy

Oncologist
Cancer ResearchMedicineOncology
1999English

Restoring Platinum Sensitivity in Recurrent Ovarian Cancer by Extending the Platinum-Free Interval: Myth or Reality?

Cancer
Cancer ResearchOncology
2017English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Rechallenge With First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer

Case Reports in Oncology
Oncology
2018English

Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Targeted Treatment of Recurrent Platinum-Resistant Ovarian Cancer: Current and Emerging Therapies

Cancer Management and Research
Oncology
2010English

Molecular Basis of Chemosensitivity of Platinum Pre-Treated Ovarian Cancer to Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy